Lead Product(s) : Rabeprazole Sodium,Levosulpiride
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Akums Launches Rabeprazole + Levosulpiride SR Capsules for GERD in India
Details : Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase, indicated for treating gastric and duodenal ulcers, as well as GERD.
Product Name : Rabeprazole-Levosulpiride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2024
Lead Product(s) : Rabeprazole Sodium,Levosulpiride
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Seoul National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2021
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Seoul National University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 26, 2019
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Ildong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2019
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Ildong Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2017
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Proton Pump Inhibitors on Palpitations
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 11, 2016
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2016
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 16, 2015
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2015
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 18, 2015
Lead Product(s) : Rabeprazole Sodium
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
